Current Clinical Trials

Meru Health: Turmeric Study *

Our study focuses on determining the feasibility of asking our patients to take a daily curcumin-with-black-pepper supplement and determining whether doing so is associated with a reduction in inflammation markers (high sensitivity c-reactive protein and interleukin-6) as well as mental health symptoms (depression, anxiety, etc.) without any associated harms. All participants will receive the 12-week Meru Health Program, with one group taking mailed turmeric supplements. 

Impact of a ketogenic diet on metabolic and psychiatric health in patients with schizophrenia or bipolar illness*

To initiate a low-carbohydrate, high-fat ketogenic dietary intervention among a small cohort of outpatients with either schizophrenia or bipolar illness and comorbid overweight/obesity currently taking psychotropic medications.

Stanford-affiliated

FDA Approved Medication to Reduce Binge Eating and/or Purging*

This study will demonstrate the efficacy of Qsymia versus placebo in treating bulimia nervosa and binge eating disorder.

Stanford-affiliated

Ketogenic diet for psychotic disorders

This randomised, controlled pilot study aims to investigate the feasibility of a Modified Ketogenic Diet intervention protocol in psychotic inpatients, and the potential impact of this intervention on psychotic symptoms, depressive and anxiety symptoms, and functioning in patients with psychotic symptoms / psychotic disorder.

Externally-conducted